Research advances and challenges in herb-induced liver injury

Chenghai LIU

doi:10.12449/JCH240801

Volume 40 Issue 8

Aug. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(8): 1505-1511

PDF( 791 KB)

Research advances and challenges in herb-induced liver injury

DOI: 10.12449/JCH240801

Chenghai LIU^{1, 2, 3
,
,
,}

1.
Institute of Liver Diseases，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China
2.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine，Shanghai 201203，China
3.
Key Laboratory of Liver and Kidney Diseases，Ministry of Education，Shanghai 201203，China

Research funding:

Shanghai TCM Development Three-Year Action Plan Project (ZY（2018-2020）-CCCX-5001);

Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project (20Z21900100);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)

More Information

Corresponding author: LIU Chenghai， chenghailiu@hotmail.com （ORCID： 0000-0002-1696-6008）
Received Date: 2024-06-26
Accepted Date: 2024-07-10
Published Date: 2024-08-25

Abstract

Abstract

Herb-induced liver injury （HILI） shows a high incidence rate and has great impacts on the clinical medication safety of traditional Chinese medicine and the healthy development of the industry. In recent years， the research on HILI has attracted wide attention and made remarkable progress， and related clinical diagnosis and treatment guidelines have been formulated and updated by the academic organizations in China and globally. This article compares the recent guidelines on HILI formulated by different organizations and elaborates on the main achievements in terms of mechanism of toxicity， clinical diagnosis and disease assessment， risk factors， and clinical prevention and treatment， and it also proposes the unmet needs， the research difficulties that need to be taken seriously， and possible prevention and treatment strategies.
- Drugs， Chinese Herbal,
- Chemical and Drug Induced Liver Injury,
- Toxic Mechanism,
- Diagnosis,
- Risk Factors,
- Therapeutics

FullText(HTML)

References(41)

References

[1]	SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156( 8): 2230- 2241. e 11. DOI: 10.1053/j.gastro. 2019. 02.002.
[2]	ZHENG E, SANDHU N, NAVARRO V. Drug-induced liver injury secondary to herbal and dietary supplements[J]. Clin Liver Dis, 2020, 24( 1): 141- 155. DOI: 10.1016/j.cld.2019.09.009.
[3]	NAVARRO VJ, BARNHART H, BONKOVSKY HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network[J]. Hepatology, 2014, 60( 4): 1399- 1408. DOI: 10.1002/hep.27317.
[4]	VUPPALANCHI R, BONKOVSKY HL, AHMAD J, et al. Garcinia cambogia, either alone or in combination with green tea, causes moderate to severe liver injury[J]. Clin Gastroenterol Hepatol, 2022, 20( 6): e1416- e1425. DOI: 10.1016/j.cgh.2021.08.015.
[5]	JING J, WANG RL, ZHAO XY, et al. Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb-Polygonum multiflorum thunb. induced liver injury: A case-control study from a specialised liver disease center in China[J]. BMJ Open, 2019, 9( 1): e023567. DOI: 10.1136/bmjopen-2018-023567.
[6]	Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J].[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176. 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
[7]	FONTANA RJ, LIOU I, REUBEN A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury[J]. Hepatology, 2023, 77( 3): 1036- 1065. DOI: 10.1002/hep.32689.
[8]	DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15( 2): 258- 282. DOI: 10.1007/s12072-021-10144-3.
[9]	Council for International Organizations of Medical Sciences. Drug-induced liver injury(DILI): Current status and future directions for drug development and the post-market setting[M]. Geneva, 2020.
[10]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70( 6): 1222- 1261. DOI: 10.1016/j.jhep. 2019. 02.014.
[11]	State Drug Administration. Technical guidelines for clinical evaluation of liver injury induced by traditional Chinese medicine[J]. J Clin Hepatol, 2018, 34( 7): 1403- 1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008. 国家药品监督管理局. 中药药源性肝损伤临床评价技术指导原则[J]. 临床肝胆病杂志, 2018, 34( 7): 1403- 1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008.
[12]	World Health Organization. General guidelines for methodologies on research and evaluation of traditional medicine[M]. Geneva: World Health Organization, 2000.
[13]	YU YC, FAN Y, CHEN CW. Research status and prospect of liver injury related to herbs and dietary supplements[J]. Chin Hepatol, 2017, 22( 4): 296- 300. DOI: 10.14000/j.cnki.issn.1008-1704.2017.04.003. 于乐成, 范晔, 陈成伟. 草药和膳食补充剂相关肝损伤的研究现状及展望[J]. 肝脏, 2017, 22( 4): 296- 300. DOI: 10.14000/j.cnki.issn.1008-1704.2017.04.003.
[14]	JING J, WANG RL, BAI ZF, et al. Interpretation on consensus on drug-induced liver injury by CIOMS Working Group: liver injury attributed to herbal and dietary supplements[J]. China J Chin Mater Med, 2023, 48( 9): 2552- 2556. DOI: 10.19540/j.cnki.cjcmm.20230123.501. 景婧, 王睿林, 柏兆方, 等. CIOMS《药物性肝损伤国际共识》解读——草药和膳食补充剂(HDS)致肝损伤[J]. 中国中药杂志, 2023, 48( 9): 2552- 2556. DOI: 10.19540/j.cnki.cjcmm.20230123.501.
[15]	LIN N, JIANG Q, LIU W, et al. Editorial explanation for clinical practice guideline for Tripterygium Glycosides/Tripterygium wilfordii tablets in treatment of rheumatoid arthritis[J]. China J Chin Mater Med, 2020, 6( 17): 4154- 4157. 林娜, 姜泉, 刘维, 等.《雷公藤多苷/雷公藤片治疗类风湿关节炎用药指南》编制说明[J]. 中国中药杂志, 2020, 6( 17): 4154- 4157.
[16]	GABBI C, BERTOLOTTI M. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381( 14): 1395- 1396. DOI: 10.1056/NEJMc1911063.
[17]	LI M, LI RR, LIU CH. Clinic diagnosis and treatment of herb-induced liver injury[J]. Chin J Pharmacovigil, 2023, 20( 2): 127- 131. DOI: 10.19803/j.1672-8629.20220661. 李盟, 李容容, 刘成海. 中草药引起肝损伤的临床诊治与用药[J]. 中国药物警戒, 2023, 20( 2): 127- 131. DOI: 10.19803/j.1672-8629.20220661.
[18]	ARLT VM, STIBOROVA M, SCHMEISER HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review[J]. Mutagenesis, 2002, 17( 4): 265- 277. DOI: 10.1093/mutage/17.4.265.
[19]	STIBOROVÁ M, FREI E, BREUER A, et al. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy[J]. Exp Toxicol Pathol, 1999, 51( 4-5): 421- 427. DOI: 10.1016/S0940-2993(99)80033-5.
[20]	JIANG HY, BAO YN, LIN FM, et al. Triptolide regulates oxidative stress and inflammation leading to hepatotoxicity via inducing CYP2E1[J]. Hum Exp Toxicol, 2021, 40( 12_suppl): S775- S787. DOI: 10.1177/09603271211056330.
[21]	LI J, SHEN FH, GUAN CW, et al. Activation of Nrf2 protects against triptolide-induced hepatotoxicity[J]. PLoS One, 2014, 9( 7): e100685. DOI: 10.1371/journal.pone.0100685.
[22]	LI CP, RAO T, CHEN XP, et al. HLA-B*35:01 allele is a potential biomarker for predicting Polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70( 1): 346- 357. DOI: 10.1002/hep.30660.
[23]	REMASH D, PRINCE DS, MCKENZIE C, et al. Immune checkpoint inhibitor-related hepatotoxicity: A review[J]. World J Gastroenterol, 2021, 27( 32): 5376- 5391. DOI: 10.3748/wjg.v27.i32.5376.
[24]	LI M, LUO Q, CHEN X, et al. Screening of major hepatotoxic components of Tripterygium wilfordii based on hepatotoxic injury patterns[J]. BMC Complement Med Ther, 2023, 23( 1): 9. DOI: 10.1186/s12906-023-03836-w.
[25]	MU GD, NIU M, GAO YJ, et al. Construction and application of liver injury risk prediction model of Chinese medicinals based on indirect toxicity[J]. J Tradit Chin Med, 2023, 64( 17): 1763- 1770. DOI: 10.13288/j.11-2166/r.2023.17.008. 母光頔, 牛明, 高云娟, 等. 基于间接毒性认知的中药肝损伤风险预测模式的构建及应用[J]. 中医杂志, 2023, 64( 17): 1763- 1770. DOI: 10.13288/j.11-2166/r.2023.17.008.
[26]	WANG XY, LI WX, ZHANG H, et al. The mechanism of Psoralea fructus induced idiosyncratic liver injury based on metabolomics[J]. Chin J Pharmacovigil, 2021, 18( 11): 1014- 1019. DOI: 10.19803/j.1672-8629.2021.11.04. 王晓艳, 李伟霞, 张辉, 等. 基于代谢组学的补骨脂致特异质肝损伤机制研究[J]. 中国药物警戒, 2021, 18( 11): 1014- 1019. DOI: 10.19803/j.1672-8629.2021.11.04.
[27]	MA J, XIA QS, FU PP, et al. Pyrrole-protein adducts-A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity[J]. J Food Drug Anal, 2018, 26( 3): 965- 972. DOI: 10.1016/j.jfda.2018.05.005.
[28]	XU ZN, ZHAO YQ, CHEN SY, et al. Advantage and risk analysis on combination of traditional Chinese medicines and Western medicines[J]. Chin Tradit Herb Drugs, 2023, 54( 2): 408- 415. DOI: 10.7501/j.issn.0253-2670.2023.02.007. 徐振娜, 赵逸卿, 陈思宇, 等. 中西药联合用药的优势及风险分析[J]. 中草药, 2023, 54( 2): 408- 415. DOI: 10.7501/j.issn.0253-2670.2023.02.007.
[29]	DING ZH, ZHANG YQ, LIN N. Component-effect/toxicity-target correlations of Tripterygium wilfordii in terms of lipid metabolism[J]. Chin J Pharmacovigil, 2023, 20( 5): 489- 495. DOI: 10.19803/j.1672-8629.20220734. 丁子禾, 张彦琼, 林娜. 从脂质代谢途径探讨中药雷公藤“物-效/毒-靶”关联性的研究现状与展望[J]. 中国药物警戒, 2023, 20( 5): 489- 495. DOI: 10.19803/j.1672-8629. 20220734.
[30]	HUANG JF, ZHAO Q, DAI MY, et al. Gut microbiota protects from triptolide-induced hepatotoxicity: Key role of propionate and its downstream signalling events[J]. Pharmacol Res, 2020, 155: 104752. DOI: 10.1016/j.phrs.2020.104752.
[31]	BAI ZF, ZHAN XY, YAO Q, et al. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: Disease-syndrome-based toxicology[J]. Chin J Pharmacovigil, 2024, 21( 1): 6- 14. DOI: 10.19803/j.1672-8629.20230787. 柏兆方, 湛小燕, 姚清, 等. 中药安全性评价理论创新与技术突破:病证毒理学[J]. 中国药物警戒, 2024, 21( 1): 6- 14. DOI: 10.19803/j.1672-8629.20230787.
[32]	HE TT, GONG M, BAI YF, et al. Clinical analysis of two diagnosis methods for herb-induced liver injury[J]. China J Chin Mater Med, 2016, 41( 16): 3096- 3099. DOI: 10.4268/cjcmm20161626. 何婷婷, 宫嫚, 白云峰, 等. 2种药物性肝损伤诊断指南的应用分析[J]. 中国中药杂志, 2016, 41( 16): 3096- 3099. DOI: 10.4268/cjcmm20161626.
[33]	MENG Y, ZHANG MM, ZHAO XY. Evolution of causality evaluation of drug-induced liver injury: From RUCAM to RECAM[J]. Chin Hepatol, 2023, 28( 6): 631- 633. DOI: 10.14000/j.cnki.issn.1008-1704.2023.06.001. 孟尧, 张萌萌, 赵新颜. 药物性肝损伤因果关系评估演变:从RUCAM到RECAM[J]. 肝脏, 2023, 28( 6): 631- 633. DOI: 10.14000/j.cnki.issn.1008-1704.2023.06.001.
[34]	AHMAD J, BARNHART HX, BONACINI M, et al. Value of liver biopsy in the diagnosis of drug-induced liver injury[J]. J Hepatol. 2022, 76( 5): 1070- 1078. DOI: 10.1016/j.jhep.2021.12.043.
[35]	LUO Q, ZHU GR, GU HT, et al. Liver histopathological features of patients with drug-induced liver injury due to Chinese herbal medicine or Western medicine: A comparative analysis of 50 cases[J]. J Clin Hepatol, 2020, 36( 3): 596- 601. DOI: 10.3969/j.issn.1001-5256.2020.03.025. 罗琼, 朱哿瑞, 顾宏图, 等. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较[J]. 临床肝胆病杂志, 2020, 36( 3): 596- 601. DOI: 10.3969/j.issn.1001- 5256. 2020. 03.025.
[36]	Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome(2017, Nanjing)[J]. J Clin Hepatol, 2017, 3( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
[37]	LIU CH, ZHU CW. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. J Clin Hepatol, 2017, 33( 5): 829- 832. DOI: 10.3969/j.issn.1001-5256.2017.05.007. 刘成海, 朱春雾. 中草药相关药物性肝损伤的流行特点、主要原因与诊断评估[J]. 临床肝胆病杂志, 2017, 33( 5): 829- 832. DOI: 10.3969/j.issn.1001-5256.2017.05.007.
[38]	World Health Organization. Key technical issues of herbal medicines with reference to interaction with other medicines[M]. Geneva: World Health Organization, 2021.
[39]	WANG LX, WANG MM, LI YY, et al. Pharmacovigilance Guidelines for proprietary Chinese medicines[J/OL]. Chin J Chin Mat Med, 2024: 1- 7.[ 2024-07-10]. https://doi.org/10.19540/j.cnki.cjcmm.20240623.501. DOI: 10.19540/j.cnki.cjcmm.20240623.501 王连心, 王萌萌, 黎元元, 等. 中成药药物警戒指南[J/OL]. 中国中药杂志, 2024: 1- 7.[ 2024-07-10]. https://doi.org/10.19540/j.cnki.cjcmm.20240623.501. DOI: 10.19540/j.cnki.cjcmm.20240623.501
[40]	SONG HB, HAN L. Epidemiologic characteristics, risk factors and safety evaluation of traditional Chinese medicine induced liver injury[J]. Chin J Pharmacol Toxicol, 2016, 30( 4): 291- 305. DOI: 10.3867/j.issn.1000-3002.2016.04.001. 宋海波, 韩玲. 中药肝损伤的流行特点、风险因素及评价[J]. 中国药理学与毒理学杂志, 2016, 30( 4): 291- 305. DOI: 10.3867/j.issn.1000-3002.2016.04.001.
[41]	HOOFNAGLE JH, BONKOVSKY HL, PHILLIPS EJ, et al. HLA-B*35:01 and green tea-induced liver injury[J]. Hepatology, 2021, 73( 6): 2484- 2493. DOI: 10.1002/hep.31538.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (472) PDF downloads(149)

Research advances and challenges in herb-induced liver injury

DOI: 10.12449/JCH240801

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances and challenges in herb-induced liver injury

DOI: 10.12449/JCH240801

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content